Topical Imiquimod (original) (raw)

• Bernard HU. Established and potential strategies against papillomavirus infections. J Antimicrob Chemother 2004 Feb; 53(2): 137–9
  PubMed CAS Google Scholar
• Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev 1988; 10: 122–63
  PubMed CAS Google Scholar
• Leung AKC, Kellner JD, Davies HD. Genital infection with human papillomavirus in adolescents. Adv Ther 2005 May; 22(3): 187–97
  PubMed Google Scholar
• American Cancer Society. Detailed guide: skin cancer — nonme-lanoma [online]. Available from URL: http://www.cancer.org [Accessed 2007 Mar 21]
• Bath-Hextall F, Perkins W, Bong J, et al. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev 2007; (1): CD003412
• Schön M, Schön MP. The antitumoral mode of action of imiquimod and other imidazoquinolines. Curr Med Chem 2007; 14(6): 681–7
  PubMed Google Scholar
• Li VW, Li WW, Talcott KE, et al. Imiquimod as an antiangi-ogenic agent. J Drugs Dermatol 2005 Nov; 4(6): 708–17
  PubMed Google Scholar
• Perry CM, Lamb HM. Topical imiquimod: a review of its use in genital warts. Drugs 1999 Aug; 58(2): 375–90
  PubMed CAS Google Scholar
• Pasmatzi ES, Chaidaroglou A, Sakkis T, et al. Short-term topical application of imiquimod induces systemic immunomodu-lation in healthy individuals [abstract]. J Immunother 2006 Nov; 29(6): 668
  Google Scholar
• 3M Health Care Limited. Aldara prescribing information [online]. Available from URL: http://www.fda.gov [Accessed 2007 Jul 10]
• Tyring SK, Arany I, Stanley MA, et al. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. J Infect Dis 1998 Aug; 178(2): 551–5
  PubMed CAS Google Scholar
• Jacobs S, Grussendorf-Conen E-I, Rösener I, et al. Molecular analysis of the effect of topical imiquimod treatment of HPV 2/ 27/57-induced common warts. Skin Pharmacol Physiol 2004 Sep; 17(5): 258–66
  PubMed CAS Google Scholar
• Kreuter A, Brockmeyer NH, Weissenborn SJ, et al. 5% Imiquimod suppositories decrease the DNA load of intra-anal HPV types 6 and 11 in HIV-infected men after surgical ablation of condylomata acuminata [letter]. Arch Dermatol 2006 Feb; 142(2): 243–4
  PubMed Google Scholar
• Kawashima M, Uchida N, Nogita T. Evaluation of skin irritation of imiquimod 5% cream by patch test [in Japanese]. J Clin Ther Med 2007; 23(5): 357–61
  Google Scholar
• Kawashima M, Uchida N, Nogita T. Evaluation of skin irritability and safety of imiquimod 5% cream in 7-day repeated application among healthy volunteers [in Japanese]. J Clin Ther Med 2007; 23(5): 363–9
  Google Scholar
• Kaidbey K, Owens M, Liberda M, et al. Safety studies of topical imiquimod 5% cream on normal skin exposed to ultraviolet radiation. Toxicology 2002 Sep 2; 178(2): 175–82
  PubMed CAS Google Scholar
• Thatcher TH, Luzina I, Fishelevich R, et al. Topical imiquimod treatment prevents UV-light induced loss of contact hypersen-sitivity and immune tolerance. J Invest Dermatol 2006 Apr; 126(4): 821–31
  PubMed CAS Google Scholar
• Owens ML, Tygum KI, Senta TA, et al. Safety assessment of topical imiquimod [abstract no. 5151]. Australas J Dermatol 1997 Jun; 38 Suppl. 2: 269
  Google Scholar
• Tygum KI, Smith SL, Myers JA, et al. Percutaneous penetration of [14C]imiquimod from a single application of cream [abstract no. PDD 7339]. Pharm Res 1995 Sep; 12 Suppl. 9: S277
  Google Scholar
• Owens ML, Bridson WE, Smith SL, et al. Percutaneous penetration of Aldara™ cream, 5% during the topical treatment of genital and perianal warts. Prim Care Update Ob Gyns 1998 Jul 1; 5(4): 151
  Google Scholar
• Harrison LI, Skinner SL, Marbury TC, et al. Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms. Arch Dermatol Res 2004 Jun; 296(1): 6–11
  PubMed CAS Google Scholar
• 3M Health Care Limited. Imiquimod: summary of product characteristics (Europe) [online]. Available from URL: www.emea.eu.int [Accessed 2007 Sep 6]
• Arican O, Guneri F, Bilgic K, et al. Topical imiquimod 5% cream in external anogenital warts: a randomized, double-blind, placebo-controlled study. J Dermatol 2004 Aug; 31(8): 627–31
  PubMed CAS Google Scholar
• Beutner KR, Spruance SL, Hougham AJ, et al. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 1998 Feb; 38(2 Pt 1): 230–9
  PubMed CAS Google Scholar
• Beutner KR, Tyring SK, Trofatter Jr KF, et al. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother 1998 Apr; 42(4): 789–94
  PubMed CAS Google Scholar
• Edwards L, Ferenczy A, Eron L, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol 1998 Jan; 134(1): 25–30
  PubMed CAS Google Scholar
• Nakagawa H. Randomized, double-blind, dose-response study of imiquimod cream in patients with external genital/perianal warts (condyloma acuminatum). Jpn J Sex Transm Dis 2007; 18(1): 134–44
  Google Scholar
• Romero-Sanchez A, Castro-Castañeda B, Abad-Gastelum MA, et al. Comparative study using 5% imiquimod cream vs 1 % 5-fluorouracil cream for the treatment of genital warts in male patients [abstract no. L-894]. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Sep 22; Chicago (IL), 457
• Sauder DN, Skinner RB, Fox TL, et al. Topical imiquimod 5% cream as an effective treatment for external genital and perianal warts in different patient populations. Sex Transm Dis 2003 Feb; 30(2): 124–8
  PubMed CAS Google Scholar
• Schöfer H, Van Ophoven A, Henke U, et al. Randomized, comparative trial on the sustained efficacy of topical imiquimod 5% cream versus conventional ablative methods in external anogenital warts. Eur J Dermatol 2006 Nov; 16(6): 642–8
  PubMed Google Scholar
• Kaspari M, Gutzmer R, Kaspari T, et al. Application of imiquimod by suppositories (anal tampons) efficiently prevents recurrences after ablation of anal canal condyloma. Br J Dermatol 2002; 147: 757–9
  PubMed CAS Google Scholar
• Fife KH, Ferenczy A, Douglas Jr JM, et al. Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily, or three times a day. Sex Transm Dis 2001 Apr; 28(4): 226–31
  PubMed CAS Google Scholar
• Trofatter Jr KF, Ferenczy A, Fife KH, et al. Increased frequency of dosing of imiquimod 5% cream in the treatment of external genital warts in women. Int J Gynaecol Obstet 2002 Feb; 76(2): 191–3
  PubMed Google Scholar
• Garland SM, Waddell R, Mindel A, et al. An open-label phase II pilot study investigating the optimal duration of imiquimod 5% cream for the treatment of external genital warts in women. Int J STD AIDS 2006 Jul; 17(7): 448–52
  PubMed CAS Google Scholar
• Alam M, Stiller M. Direct medical costs for surgical and medical treatment of condylomata acuminata. Arch Dermatol 2001 Mar; 137(3): 337–41
  PubMed CAS Google Scholar
• Langley PC, Tyring SK, Smith MH. The cost effectiveness of patient-applied versus provider-administered intervention strategies for the treatment of external genital warts. Am J Manag Care 1999 Jan; 5(1): 69–77
  PubMed CAS Google Scholar
• Williams P, von Krogh G. The cost-effectiveness of patient-applied treatments for anogenital warts. Int J STD AIDS 2003 Apr; 14(4): 228–34
  PubMed Google Scholar
• Grussendorf-Conen E-I, Jacobs S, Rübben A, et al. Topical 5% imiquimod long-term treatment of cutaneous warts resistant to standard therapy modalities. Dermatology 2002; 205(2): 139–45
  PubMed CAS Google Scholar
• Hengge UR, Esser S, Schultewolter T, et al. Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum. Br J Dermatol 2000 Nov; 143(5): 1026–31
  PubMed CAS Google Scholar
• Micali G, Dall’Oglio F, Nasca MR. An open label evaluation of the efficacy of imiquimod 5% cream in the treatment of recalcitrant subungual and periungual cutaneous warts. J Dermatolog Treat 2003 Dec; 14(4): 233–6
  PubMed CAS Google Scholar
• Grussendorf-Conen E-I, Jacobs S. Efficacy of imiquimod 5% cream in the treatment of recalcitrant warts in children. Pediatr Dermatol 2002 May; 19(3): 263–6
  PubMed Google Scholar
• Theos AU, Cummins R, Silverberg NB, et al. Effectiveness of imiquimod cream 5% for treating childhood molluscum contagiosum in a double-blind, randomized pilot trial. Cutis 2004 Aug; 74(2): 134–8, 141–2
  PubMed Google Scholar
• Schacker TW, Conant M, Thoming C, et al. Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis: a phase II, randomized, double-blind, placebo-controlled study. Antimicrob Agents Chemother 2002 Oct; 46(10): 3243–8
  PubMed CAS Google Scholar
• Mandekou-Lefaki I, Delli F, Teknetzis A, et al. Successful treatment of seborrheic keratosis with imiquimod 5% cream. Int J Immunother 2004; 20(1): 23–8
  CAS Google Scholar
• Berman B, Kaufman J. Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids. J Am Acad Dermatol 2002 Oct; 47 Suppl. 4: S209–11
  PubMed Google Scholar
• Martín-García RF, Busquets AC. Postsurgical use of imiquimod 5% cream in the prevention of earlobe keloid recurrences: results of an open-label, pilot study. Dermatol Surg 2005 Nov; 31(11 Pt 1): 1394–8
  PubMed Google Scholar
• Redondo P, Del Olmo J, Idoate M. Angiolymphoid hyperplasia with eosinophilia successfully treated with imiquimod [letter]. Br J Dermatol 2004 Nov; 151(5): 1110–1
  PubMed CAS Google Scholar
• Taverna JA, Stefanato CM, Wax FD, et al. Adult cutaneous Langerhans cell histiocytosis responsive to topical imiquimod [letter]. J Am Acad Dermatol 2006 May; 54(5): 911–3
  PubMed Google Scholar
• Crawford R, Holmes D, Meymandi S. Comparative study of the efficacy of combined imiquimod 5% cream and intralesional meglumine antimoniate versus imiquimod 5% cream and intralesional meglumine antimoniate alone for the treatment of cutaneous leishmaniasis [abstract no. P1706]. J Am Acad Dermatol 2005 Mar; 52(3): 118
  Google Scholar
• Gul U, Gönül M, Çakmak SK, et al. A case of generalized discoid lupus erythematosus: successful treatment with imiquimod cream 5%. Adv Ther 2006 Sep; 23(5): 787–92
  PubMed Google Scholar
• Kelly SC, Purcell SM. Imiquimod therapy for elastosis perforans serpiginosa. Arch Dermatol 2006 Jul; 142(7): 829–30
  PubMed Google Scholar
• Chan CC, Thong HY, Chan YC, et al. Human papillomavirus type 5 infection in a patient with Hailey-Hailey disease successfully treated with imiquimod [letter]. Br J Dermatol 2007 Mar; 156(3): 579–81
  PubMed CAS Google Scholar
• Kuwahara RT, Skinner Jr RB. Granuloma annulare resolved with topical application of imiquimod [letter]. Pediatr Dermatol 2002 Jul; 19(4): 368–9
  PubMed Google Scholar
• Martinez MI, Sanchez-Carpintero I, North PE, et al. Infantile hemangioma: clinical resolution with 5% imiquimod cream. Arch Dermatol 2002 Jul; 138(7): 881–4
  PubMed Google Scholar
• Welsh O, Olazaran Z, Gómez M, et al. Treatment of infantile hemangiomas with short-term application of imiquimod 5% cream. J Am Acad Dermatol 2004 Oct; 51(4): 639–42
  PubMed Google Scholar
• Hazen PG, Carney JF, Engstrom CW, et al. Proliferating hemangioma of infancy: successful treatment with topical 5% imiquimod cream. Pediatr Dermatol 2005; 22(3): 254–6
  PubMed Google Scholar
• Dytoc M, Ting PT, Man J, et al. First case series on the use of imiquimod for morphoea. Br J Dermatol 2005 Oct; 153(4): 815–20
  PubMed CAS Google Scholar
• Urquhart JL, Weston WL. Treatment of multiple trichoepithe-liomas with topical imiquimod and tretinoin. Pediatr Dermatol 2005 Jan; 22(1): 67–70
  PubMed Google Scholar
• Goldenberg G, Krowchuk DP, Jorizzo JL. Successful treatment of a therapy-resistant pyogenic granuloma with topical imiquimod 5% cream. J Dermatolog Treat 2006; 17(2): 121–3
  PubMed CAS Google Scholar
• Ezzell TI, Fromowitz JS, Ramos-Caro FA. Recurrent pyogenic granuloma treated with topical imiquimod [letter]. J Am Acad Dermatol 2006 May; 54 Suppl. 5: S244–5
  PubMed Google Scholar
• Baumann LS, Halem ML. Lip silicone granulomatous foreign body reaction treated with aldara (imiquimod 5%). Dermatol Surg 2003 Apr; 29(4): 429–32
  PubMed Google Scholar
• Stockfleth E, Röwert J, Arndt R, et al. Detection of human papillomavirus and response to topical 5% imiquimod in a case of stucco keratosis. Br J Dermatol 2000 Oct; 143(4): 846–50
  PubMed CAS Google Scholar
• Bhaumik J. Vulvitis circumscripta plasmacellularis: success with a modified treatment regimen using imiquimod. J Obstet Gynaecol 2006 Jan; 26(1): 72
  PubMed CAS Google Scholar
• Ee HL, Yosipovitch G, Chan R, et al. Resolution of vulvitis circumscripta plasmacellularis with topical imiquimod: two case reports. Br J Dermatol 2003 Sep; 149(3): 638–41
  PubMed CAS Google Scholar
• Alomar A, Bichel J, McRae S. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol 2007; 157(1): 133–41
  PubMed CAS Google Scholar
• Jorizzo J, Dinehart S, Matheson R, et al. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol 2007; 57(2): 265–8
  PubMed Google Scholar
• Korman N, Moy R, Ling M, et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol 2005 Apr; 141(4): 467–73
  PubMed CAS Google Scholar
• Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004 May; 50(5): 714–21
  PubMed Google Scholar
• Szeimies R-M, Gerritsen M-J, Gupta G, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol 2004 Oct; 51(4): 547–55
  PubMed Google Scholar
• Tanghetti E, Werschler P. Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp. J Drugs Dermatol 2007 Feb; 6(2): 144–7
  PubMed Google Scholar
• Stockfleth E, Benninghoff B, Busch J-O, et al. Long-term clearance of multiple actinic keratoses after topical treatment with imiquimod (5%) [abstract no. P469]. J Am Acad Dermatol 2004 Mar; 50 Suppl. 3: P121. Plus poster presented at the 62nd annual meeting of the American Academy of Dermatology; 2004 Feb; Washington, DC
• European Medicines Agency. Aldara scientific discussion [online]. Available from URL: http://www.emea.europa.eu [Accessed 2007 Jul 11]
• Lee PK, Harwell WB, Loven KH, et al. Long-term clinical outcomes following treatment of actinic keratosis with imiquimod 5% cream. Dermatol Surg 2005 Jun; 31(6): 659–64
  PubMed CAS Google Scholar
• Abbasakoor F, Boulos PB. Anal intraepithelial neoplasia. Br J Surg 2005 Mar; 92(3): 277–90
  PubMed CAS Google Scholar
• Patel GK, Goodwin R, Chawla M, et al. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen’s disease): a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2006 Jun; 54(6): 1025–32
  PubMed Google Scholar
• Mackenzie-Wood A, Kossard S, de Launey J, et al. Imiquimod 5% cream in the treatment of Bowen’s disease. J Am Acad Dermatol 2001 Mar; 44(3): 462–70
  PubMed CAS Google Scholar
• Le T, Menard C, Hicks-Boucher W, et al. Final results of a phase 2 study using continuous 5% Imiquimod cream application in the primary treatment of high-grade vulva intraepithelial neoplasia. Gynecol Oncol 2007; 106(3): 579–84
  PubMed CAS Google Scholar
• Todd RW, Etherington IJ, Luesley DM. The effects of 5% imiquimod cream on high-grade vulval intraepithelial neoplasia. Gynecol Oncol 2002 Apr; 85(1): 67–70
  PubMed CAS Google Scholar
• Wendling J, Saiag P, Berville-Levy S, et al. Treatment of undifferentiated vulvar intraepithelial neoplasia with 5% imiquimod cream: a prospective study of 12 cases. Arch Dermatol 2004 Oct; 140(10): 1220–4
  PubMed CAS Google Scholar
• van Seters M, Fons G, van Beurden M. Imiquimod in the treatment of multifocal vulvar intraepithelial neoplasia 2/3: results of a pilot study. J Reprod Med 2002 Sep; 47(9): 701–5
  PubMed Google Scholar
• Marchitelli C, Secco G, Perrotta M, et al. Treatment of bowe-noid and basaloid vulvar intraepithelial neoplasia 2/3 with imiquimod 5% cream. J Reprod Med 2004 Nov; 49(11): 876–82
  PubMed Google Scholar
• Buck HW, Guth KJ. Treatment of vaginal intraepithelial neoplasia (primarily low grade) with imiquimod 5% cream. J Low Genit Tract Dis 2003 Oct; 7(3): 290–3
  PubMed Google Scholar
• Boonchai W. Treatment of precancerous and cancerous lesions of chronic arsenicism with 5% imiquimod cream [letter]. Arch Dermatol 2006 Apr; 142(4): 531–2
  PubMed Google Scholar
• Sachse MM, Zimmermann J, Bahmer FA. Efficiency of topical imiquimod 5% cream in the management of chronic radiation dermatitis with multiple neoplasias. Eur J Dermatol 2006; 16(1): 56–8
  PubMed Google Scholar
• Berthelot C, Dickerson MC, Rady P, et al. Treatment of a patient with epidermodysplasia verruciformis carrying a novel EVER2 mutation with imiquimod. J Am Acad Dermatol 2007; 56(5): 882–6
  PubMed Google Scholar
• Hughes PSH. Treatment of lymphomatoid papulosis with imiquimod 5% cream [letter]. J Am Acad Dermatol 2006 Mar; 54(3): 546–7
  PubMed Google Scholar
• Agarwal S, Berth-Jones J. Porokeratosis of Mibelli: successful treatment with 5% imiquimod cream [letter]. Br J Dermatol 2002 Feb; 146(2): 338–9
  PubMed CAS Google Scholar
• Harrison S, Sinclair R. Porokeratosis of Mibelli: successful treatment with topical 5% imiquimod cream. Australas J Dermatol 2003 Nov; 44(4): 281–3
  PubMed Google Scholar
• Jain S. Successful treatment of porokeratosis of Mibelli with imiquimod 5% cream [letter]. Clin Exp Dermatol 2005 Mar; 31(2): 302–3
  Google Scholar
• Montes-De-Oca-Sánchez G, Tirado-Sánchez A, García-Ramírez V. Porokeratosis of Mibelli of the axillae: treatment with topical imiquimod. J Dermatolog Treat 2006; 17(5): 319–20
  PubMed Google Scholar
• Weisberg NK, Varghese M. Therapeutic response of a brother and sister with xeroderma pigmentosum to imiquimod 5% cream. Dermatol Surg 2002 Jun; 28(6): 518–23
  PubMed Google Scholar
• Nijsten T, Lapière K, Lambert J. A patient with xeroderma pigmentosum treated with imiquimod 5% cream [letter]. J Am Acad Dermatol 2005 Jan; 52(1): 170–1
  PubMed Google Scholar
• Somani N, Martinka M, Crawford RI, et al. Treatment of atypical nevi with imiquimod 5% cream. Arch Dermatol 2007 Mar; 143(3): 379–85
  PubMed CAS Google Scholar
• Dusza SW, Delgado R, Busam KJ, et al. Treatment of dysplastic nevi with 5% imiquimod cream, a pilot study. J Drugs Dermatol 2006 Jan; 5(1): 56–62
  PubMed Google Scholar
• Geisse JK, Rich P, Pandya A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 2002 Sep; 47(3): 390–8
  PubMed Google Scholar
• Geisse J, Caro I, Lindholm J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004 May; 50(5): 722–33
  PubMed Google Scholar
• Schulze HJ, Cribier B, Requena L, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol 2005 May; 152(5): 939–47
  PubMed CAS Google Scholar
• Shumack S, Robinson J, Kossard S, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol 2002 Sep; 138(9): 1165–71
  PubMed CAS Google Scholar
• Eigentler TK, Kamin A, Weide BM, et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma (in ENG]. J Am Acad Dermato 2007; 57(4): 616–21
  Google Scholar
• Gollnick H, Barona CG, Frank RG, et al. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe. Eur J Dermatol 2005 Sep; 15(5): 374–81
  PubMed CAS Google Scholar
• Quirk C, Gebauer K, Owens M, et al. Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks. Australas J Dermatol 2006 Nov; 47(4): 258–65
  PubMed Google Scholar
• Vidal D, Matías-Guiu X, Alomar A. Fifty-five basal cell carcinomas treated with topical imiquimod: outcome at 5-year follow-up [letter]. Arch Dermatol 2007 Feb; 143(2): 266–8
  PubMed Google Scholar
• Spencer JM. Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma. Dermatol Surg 2006 Jan; 32(1): 63–9
  PubMed CAS Google Scholar
• Rigel D, Torres A, Ely H. Effectiveness of curettage and 5% imiquimod cream in the treatment of basal cell carcinoma: clinical and cosmetic evaluation [abstract no. P2420]. J Am Acad Dermatol 2006 Mar; 54 (3 Suppl. 1): AB174
  Google Scholar
• De Cock E, Nuijten MJ, Hollestein A, et al. Cost-effectiveness model of Aldara™ (imiquimod) cream, 5% in superficial basal cell carcinoma in The Netherlands [abstract no. PSN4]. Value Health 2005 Nov; 8(6): A144. Plus poster presented at the ISPOR Eighth Annual European Congress; 2005 Nov 6; Florence
  Google Scholar
• Sverre JM, Kristensen FKO, Hamel-Gariépy L, et al. Cost-effectiveness analysis: aldara™ (imiquimod) cream, 5% in the treatment of superficial basal cell carcinoma in Norway [abstract no. PSN2]. Value Health 2005 Nov; 8(6): A143. Plus poster presented at the ISPOR Eighth Annual European Congress; 2005 Nov 6; Florence
  Google Scholar
• Green DS, Bodman-Smith MD, Dalgleish AG, et al. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol 2007 Feb; 156(2): 337–45
  PubMed CAS Google Scholar
• Fisher GH, Lang PG. Treatment of melanoma in situ on sun-damaged skin with topical 5% imiquimod cream complicated by the development of invasive disease [letter]. Arch Dermatol 2003 Jul; 139(7): 945–7
  PubMed Google Scholar
• Fleming CJ, Bryden AM, Evans A, et al. A pilot study of treatment of lentigo maligna with 5% imiquimod cream. Br J Dermatol 2004; 151(2): 485–8
  PubMed CAS Google Scholar
• Haque R. Topical imiquimod as an efficacious treatment for lentigo maligna [abstract no. P3]. 61st Annual Meeting of the American Academy of Dermatology poster abstracts; 2003 Mar 21; San Francisco (CA), 2
• Naylor MF, Crowson N, Kuwahara R, et al. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol 2003 Nov; 149 Suppl. 66: 66–70
  Google Scholar
• Powell AM, Russell-Jones R, Barlow RJ. Topical imiquimod immunotherapy in the management of lentigo maligna. Clin Exp Dermatol 2004 Jan; 29(1): 15–21
  PubMed CAS Google Scholar
• Wolf IH, Cerroni L, Kodama K, et al. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Arch Dermatol 2005 Apr; 141(4): 510–4
  PubMed CAS Google Scholar
• Naylor MF, Chen WR, Teague TK, et al. In situ photoimmunotherapy: a tumour-directed treatment for melanoma. Br J Dermatol 2006 Dec; 155(6): 1287–92
  PubMed CAS Google Scholar
• Konstantopoulou M, Lord MG, Macfarlane AW. Treatment of invasive squamous cell carcinoma with 5-percent imiquimod cream. Dermatol Online J 2006; 12(3): 10
  PubMed CAS Google Scholar
• Martín-García RF. Imiquimod: an effective alternative for the treatment of invasive cutaneous squamous cell carcinoma. Dermatol Surg 2005 Mar; 31(3): 371–4
  PubMed Google Scholar
• Oster-Schmidt C, Eul A. Successful treatment of a squamous cell carcinoma on the back of the hand with imiquimod 5% cream [abstract no. P2128]. Ann Dermatol Venereol 2002 Jul; 129 Suppl.: 1S787
  Google Scholar
• Li VW, Ball RA, Vasan N, et al. Antiangiogenic therapy for squamous cell carcinoma using combinatorial agents [abstract no. 3032]. J Clin Oncol 2005 Jun 1; 23 (16 Pt I Suppl.): 199
  Google Scholar
• Chong A, Loo WJ, Banney L, et al. Imiquimod 5% cream in the treatment of mycosis fungoides: a pilot study [letter]. J Dermatolog Treat 2004 Feb; 15(2): 118–9
  PubMed CAS Google Scholar
• Born AK, Schreiber K, Lukowsky A, et al. Imiquimod for the treatment of cutaneous T cell lymphoma [abstract no. 272]. J Invest Dermatol 2002 Sep; 119(3): 758
  Google Scholar
• Dendorfer M, Oppel T, Wollenberg A, et al. Topical treatment with imiquimod may induce regression of facial keratoa-canthoma. Eur J Dermatol 2003; 13(1): 80–2
  PubMed Google Scholar
• Scott DR. Apparent response of cutaneous Merkel cell tumor to topical imiquimod [letter]. Cutis 2006 Feb; 77(2): 109–10
  PubMed Google Scholar
• Jo J-H, Ko H-C, Jang H-S, et al. Infiltrative trichilemmal carcinoma treated with 5% imiquimod cream. Dermatol Surg 2005 Aug; 31(8 Pt 1): 973–6
  PubMed CAS Google Scholar
• Brown VL, Atkins CL, Ghali L, et al. Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial. Arch Dermatol 2005 Aug; 141(8): 985–93
  PubMed CAS Google Scholar
• Gilson RJC, Shupack JL, Friedman-Kien AE, et al. A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. AIDS 1999 Dec 3; 13(17): 2397–404
  PubMed CAS Google Scholar
• Cusini M, Salmaso F, Zerboni R, et al. 5% Imiquimod cream for external anogenital warts in HIV-infected patients under HAART therapy. Int J STD AIDS 2004 Jan; 15(1): 17–20
  PubMed CAS Google Scholar
• Harwood CA, Perrett CM, Brown VL, et al. Imiquimod cream 5% for recalcitrant cutaneous warts in immunosuppressed individuals. Br J Dermatol 2005 Jan; 152(1): 122–9
  PubMed CAS Google Scholar
• Wieland U, Brockmeyer NH, Weissenborn SJ, et al. Imiquimod treatment of anal intraepithelial neoplasia in HIV-positive men. Arch Dermatol 2006 Nov; 142(11): 1438–44
  PubMed CAS Google Scholar
• Brown Jr CW, O’Donoghue M, Moore J, et al. Recalcitrant molluscum contagiosum in an HIV-afflicted male treated successfully with topical imiquimod. Cutis 2000 Jun; 65(3): 363–6
  PubMed Google Scholar
• Buckley R, Smith K. Topical imiquimod therapy for chronic giant molluscum contagiosum in a patient with advanced human immunodeficiency virus 1 disease. Arch Dermatol 1999 Oct; 135(10): 1167–9
  PubMed CAS Google Scholar
• Liota E, Smith KJ, Buckley R, et al. Imiquimod therapy for molluscum contagiosum. J Cutan Med Surg 2000 Apr; 4(2): 76–82
  PubMed CAS Google Scholar
• Strauss RM, Doyle EL, Mohsen AH, et al. Successful treatment of molluscum contagiosum with topical imiquimod in a severely immunocompromised HIV-positive patient. Int J STD AIDS 2001 Apr; 12(4): 264–6
  PubMed CAS Google Scholar
• Ulrich C, Busch JO, Meyer T, et al. Successful treatment of multiple actinic keratoses in organ transplant patients with topical 5% imiquimod: a report of six cases. Br J Dermatol 2006 Aug; 155(2): 451–4
  PubMed CAS Google Scholar
• Vidal D, Alomar A. Efficacy of imiquimod 5% cream for basal cell carcinoma in transplant patients. Clin Exp Dermatol 2004 May; 29(3): 237–9
  PubMed CAS Google Scholar
• Eklind J, Tartler U, Maschke J, et al. Imiquimod to treat different cancers of the epidermis. Dermatol Surg 2003 Aug; 29(8): 890–6; discussion 896
  PubMed Google Scholar
• Smith KJ, Germain M, Skelton H. Squamous cell carcinoma in situ (Bowen’s disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy. Dermatol Surg 2001 Jun; 27(6): 561–4
  PubMed CAS Google Scholar
• Gardner LS, Ormond PJ. Treatment of multiple giant molluscum contagiosum in a renal transplant patient with imiquimod 5% cream [letter]. Clin Exp Dermatol 2006 May; 31(3): 452–3
  PubMed CAS Google Scholar
• Smith KJ, Germain M, Skelton H. Bowen’s disease (squamous cell carcinoma in situ) in immunosuppressed patients treated with imiquimod 5% cream and a cox inhibitor, sulindac: potential applications for this combination of immunotherapy. Dermatol Surg 2001 Feb; 27(2): 143–6
  PubMed CAS Google Scholar
• Hanger C, Dalrymple J, Hepburn D. Systemic side effects from topical imiquimod. NZ Med J 2005 Oct 7; 118(1223): U1682
  Google Scholar
• Benson E. Imiquimod: potential risk of an immunostimulant. Australas J Dermatol 2004 May; 45(2): 123–4
  PubMed Google Scholar
• Rajan N, Langtry JAA. Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas [letter]. Clin Exp Dermatol 2005 Jan; 31(1): 140–1
  Google Scholar
• Taylor CL, Maslen M, Kapembwa M. A case of severe eczema following use of imiquimod 5% cream. Sex Transm Infect 2006 Jun; 82(3): 227–8
  PubMed CAS Google Scholar
• Wu JK, Siller G, Strutton G. Psoriasis induced by topical imiquimod. Australas J Dermatol 2004 Feb; 45(1): 47–50
  PubMed Google Scholar
• Barton JC. Angioedema associated with imiquimod [letter]. J Am Acad Dermatol 2004 Sep; 51(3): 477–8
  PubMed Google Scholar
• Chakrabarty AK, Mraz S, Geisse JK, et al. Aphthous ulcers associated with imiquimod and the treatment of actinic cheilitis. J Am Acad Dermatol 2005 Feb; 52 (2 Suppl. 1): S35–7
  Google Scholar
• Zalaudek I, Petrillo G, Argenziano G. Aphthous ulcers and imiquimod [letter]. J Am Acad Dermatol 2005 Aug; 53(2): 360–1
  PubMed Google Scholar
• McQuillan O, Higgins SP. Acute urinary retention following self treatment of genital warts with imiquimod 5% cream [letter]. Sex Transm Infect 2004 Oct; 80(5): 419–20
  PubMed CAS Google Scholar
• Lin R, Ladd Jr DJ, Powell DJ, et al. Localized pemphigus foliaceus induced by topical imiquimod treatment [letter]. Arch Dermatol 2004 Jul; 140(7): 889–90
  PubMed Google Scholar
• Trevino J, Prieto VG, Hearne R, et al. Atypical lymphocytic reaction with epidermotropism and lymphocytic vasculopathic reaction (lymphocytic vasculitis) after treatment with imiquimod [letter]. J Am Acad Dermatol 2006 Nov; 55 Suppl. 5: S123–5
  PubMed Google Scholar
• Yan J, Chen S-L, Wang H-N, et al. Meta-analysis of 5% imiquimod and 0.5% podophyllotoxin in the treatment of condylomata acuminata. Dermatology 2006; 213(3): 218–23
  PubMed CAS Google Scholar
• Centers for Disease Control and Prevention — Federal Government Agency (US). HPV infection and genital warts: sexually transmitted diseases treatment guidelines 2006 [online]. Available from URL: http://www.guidelines.gov [Accessed 2007 May 31]
• von Krogh G, Lacey CJN, Gross G, et al. European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts. Sex Transm Infect 2000 Jun; 76(3): 162–8
  Google Scholar
• Berman B, Bienstock L, Kuritzky L, et al. Actinic keratoses: sequelae and treatments. Recommendations from a consensus panel. J Fam Pract 2006 May; 55 Suppl. 5: 1–8
  Google Scholar
• National Institute for Health and Clinical Excellence. Guidance on cancer services: improving outcomes for people with skin tumours including melanoma [online]. Available from URL: http://www.nice.org.uk [Accessed 2007 Jun 5]
• Hadley G, Derry S, Moore RA. Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol 2006 Jun; 126(6): 1251–5
  PubMed CAS Google Scholar
• Falagas ME, Angelousi AG, Peppas G. Imiquimod for the treatment of actinic keratosis: A meta-analysis of randomized controlled trials [letter]. J Am Acad Dermatol 2006 Sep; 55(3): 537–8
  PubMed Google Scholar